Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Second transplant a good salvage option for children with ALL, AML, or MDS

Publish date:: March 16, 2020

Key clinical point: Second allogeneic transplant is an effective salvage therapy option after relapse in children with lymphoid cancers or myelodysplastic diseases.

Major finding: 3-year overall survival was 26% for children who had a second transplant vs. 4% for those who did not.

Study details: Retrospective study of 221 patients aged 21 years and younger who had a relapse after stem cell transplant for ALL, AML, or MDS.

Disclosures: The study was supported by St. Jude’s, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Dr. Sharma, Dr. Boelens, and Dr. Duerst reported having no relevant disclosures.

Citation:

Sharma A et al. TCT 2020, Abstract 116.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,